IREN stock surged 7.5% Thursday as analysts highlight AI data center growth, Microsoft deal, and projected $2.92B revenue ...
The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results